GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (FRA:GOV) » Definitions » Loans Receivable

Insulet (FRA:GOV) Loans Receivable : €0 Mil (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Insulet Loans Receivable?

Insulet's Loans Receivable for the quarter that ended in Mar. 2024 was €0 Mil.


Insulet Loans Receivable Historical Data

The historical data trend for Insulet's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Loans Receivable Chart

Insulet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Insulet Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Insulet Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Insulet Loans Receivable Related Terms

Thank you for viewing the detailed overview of Insulet's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet (FRA:GOV) Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.

Insulet (FRA:GOV) Headlines

No Headlines